Introducing an Entirely New Era of Innovation With Intelligence
We’re making headlines and getting the recognition we deserve for transforming innovation across industries. Read all about it here!
TargetMeld™ and RxMeld™ to provide predictive analytics and comprehensive access to emerging targets and clinical assets with a quantified probability of success
GUILFORD, Conn., Sept. 17, 2019 — InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI)
Dr. Agrawal, a biopharma Strategy and R&D leader, brings scientific and technology expertise to a world-class board of directors at InveniAI.
Focus on identifying therapies in hard to treat diseases to serve unmet patient needs
Guilford, CT., March 26, 2019 — InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI) .
Artificial intelligence and machine learning platform to drive innovation for rare disease treatments
BRANFORD, CT December 11, 2018, InveniAI® Corporation, a global leader in pioneering the
Introduction: An outbreak of respiratory illness (COVID-19 Disease) caused by a novel coronavirus, namely SARS-CoV-2, was first detected in Wuhan City, Hubei Province, China. Infection by this coronavirus has been acknowledged as a global pandemic.
As countries scramble to address the coronavirus outbreak that started in Wuhan, China, the U.S. FDA issued a new policy to help expedite the availability of a diagnostic to achieve more testing capacity in the U.S.
Artificial intelligence (AI) far too often pops up as a term used vaguely to refer to any process that appears to involve more computers than it did twenty years ago.
AI’s Role In Redefining Consumer Health & Drug Development-Featured Guest Krishnan Nandabalan, InveniAI CEO/Founder
InveniAI Corporation CEO Krishnan Nandabalan sat down with Proactive at the 2019 BIO Investor Forum in San Francisco.
Among the many examples of Artificial Intelligence, AI in healthcare is clearly one of the leaders.
Thank you Moira Gunn for a wonderful conversation with our President and CEO, Krishnan Nandabalan at #BIO2019.
This interview is part of our new AI in Healthcare series, where we interview the world’s top
Some biopharmaceutical enterprises are taking a leap of faith by reviving failed investigational therapies and aiming them towards new indications and freshly reformulated study designs.
Daniel Levine, principal of the Levine Media Group, and host of Bio Report and RARECast podcasts, interviews Dr.Krishnan Nandabalan on the propagation of data in the life sciences
Wading through oceans of information can be difficult if not impossible for scientists doing complicated research.
To date, the healthcare industry has had limited success in developing treatments for rare diseases.
Invited to attend Exclusive Bloomberg Digital Disruption Think Tank Meet
Artificial intelligence and machine learning platform to drive innovation for rare disease